Utility of DXA Monitoring in Clinical Practice

Saturday, April 1, 2023

7:00 AM – 8:00 AM

Location: Northbrook Ballroom

*Speaker(s)

William Leslie, MD, MSc, CCD

Professor of Medicine and Radiology
University of Manitoba, Canada

Disclosure(s): No financial relationships to disclose

Handouts

*Moderator(s)

TW

Thomas J. Weber, MD, CCD

Professor of Medicine
Duke University

Disclosure(s): AgNovos Healthcare (DSMB member): Other (Ongoing); HMP Global (XLH/TIO online CME lectures): Other (Ongoing); Ultragenyx: Contracted Research (PI’s must provide disclosure in this category) (Ongoing)

Disclosure(s):

William Leslie, MD, MSc, CCD: No financial relationships to disclose

Thomas Weber, MD, CCD: AgNovos Healthcare (DSMB member): Other (Ongoing); HMP Global (XLH/TIO online CME lectures): Other (Ongoing); Ultragenyx: Contracted Research (PI’s must provide disclosure in this category) (Ongoing)

DXA is critical to the assessment and management of patients with osteoporosis. We will review the current evidence on the benefits and limitations of serial DXA assessment in clinical practice.

Learning Objectives:

List ISCD positions related to least significant change (LSC) for monitoring BMD change.
Explain the benefits and controversies in BMD monitoring of untreated patients.
Explain the benefits and controversies in BMD monitoring of patients receiving anti-osteoporosis therapy.